case report aspiration during anesthesia glp-1 receptor agonist 2023 AGONISTS BEFORE GENERAL AND RESPIRATORY COMPLICATIONS GLP-1 drugs and aspiration risk

The standard regimen involves: Loading doses without neurological involvement : 1 mg intramuscularly three times a week for 2 weeks [3] [8] Loading doses with neurological involvement : 1 mg intramuscularly on alternate days until no further improvement [3] [8] Maintenance therapy : 1 mg every 23 months for life in cases of pernicious anaemia or irreversible malabsorption (every 2 months if neurological involvement) [3] [8] This aggressive approach aims to prevent irreversible neurological damage, though recovery of established neuropathy may be incomplete, particularly if treatment is delayed

Girolomoni 2009

CJC-1295 with DAC maintains elevated GH levels for up to 68 days, while Ipamorelin provides immediate release, making this a complementary strategy for mimicking natural GH rhythms

No one can lawfully sell retatrutide for human administration or compound it under U.S

While the opportunity for oral GLP-1s is substantial, realising its full potential will depend on how effectively pharmaceutical companies and CDMOs navigate the associated challenges